GRI Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $0 |
| Research and development | $6.8M | $3.8M | $3.2M | $242,000 | $5.2M |
| Operating expenses | $12.0M | $8.2M | $11.4M | $2.2M | $9.3M |
| Operating income | -$12.0M | -$8.2M | -$11.4M | -$2.2M | -$9.3M |
| Income tax expense | $3,000 | $2,000 | — | — | — |
| Net income | -$12.0M | -$8.2M | -$13.0M | -$3.2M | -$9.3M |
| Balance Sheet | |||||
| Cash and equivalents | $8.2M | $5.0M | $1.8M | $9,000 | $3.7M |
| Current assets | $8.6M | $5.6M | $2.9M | $312,000 | $8.1M |
| Total assets | $8.7M | $5.7M | $3.0M | $383,000 | $8.3M |
| Current liabilities | $2.6M | $1.6M | $2.7M | $2.0M | $2.4M |
| Total liabilities | $2.7M | $1.7M | $2.7M | $2.0M | $2.5M |
| Stockholders' equity | $6.0M | $4.0M | $259,000 | -$1.6M | -$4.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
| Depreciation and amortization | $4,000 | $4,000 | $4,000 | $3,000 | — |
| Stock-based compensation | $793,000 | $148,000 | $388,000 | $25,000 | $626,000 |
| Capital expenditure | $3,000 | $0 | $8,000 | $3,000 | $0 |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M | -$1.1M | -$8.3M |
Shares outstanding 1.8M · Free float 13.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.